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BACKGROUND & AIMS: Most patients with Crohn’s disease
(CD) eventually require an intestinal resection. However, CD
frequently recurs after resection. We performed a randomized
trial to compare the ability of inﬂiximab vs placebo to prevent
CD recurrence. METHODS: We evaluated the efﬁcacy of
inﬂiximab in preventing postoperative recurrence of CD in
297 patients at 104 sites worldwide from November 2010
through May 2012. All study patients had undergone ileoco-
lonic resection within 45 days before randomization. Patients
were randomly assigned (1:1) to groups given inﬂiximab
(5 mg/kg) or placebo every 8 weeks for 200 weeks. The
primary end point was clinical recurrence, deﬁned as a
composite outcome consisting of a CD Activity Index score
>200 and a 70-point increase from baseline, and endo-
scopic recurrence (Rutgeerts score i2, determined by a
central reader) or development of a new or re-draining ﬁstula
or abscess, before or at week 76. Endoscopic recurrence was
a major secondary end point. RESULTS: A smaller proportion
of patients in the inﬂiximab group had a clinical recurrence
before or at week 76 compared with the placebo group, but
this difference was not statistically signiﬁcant (12.9% vs
20.0%; absolute risk reduction [ARR] with inﬂiximab, 7.1%;
95% conﬁdence interval: 1.3% to 15.5%; P ¼ .097). A
signiﬁcantly smaller proportion of patients in the inﬂiximab
group had endoscopic recurrence compared with the placebo
group (30.6% vs 60.0%; ARR with inﬂiximab, 29.4%; 95%
conﬁdence interval: 18.6% to 40.2%; P < .001). Additionally,
a signiﬁcantly smaller proportion of patients in the inﬂix-
imab group had endoscopic recurrence based only on Rut-
geerts scores i2 (22.4% vs 51.3%; ARR with inﬂiximab,
28.9%; 95% conﬁdence interval: 18.4% to 39.4%; P < .001).
Patients previously treated with anti-tumor necrosis factor
agents or those with more than 1 resection were at greater
risk for clinical recurrence. The safety proﬁle of inﬂiximab
was similar to that from previous reports. CONCLUSIONS:
Inﬂiximab is not superior to placebo in preventing clinicalrecurrence after CD-related resection. However, inﬂiximab
does reduce endoscopic recurrence. ClinicalTrials.gov ID
NCT01190839.Keywords: PREVENT; Anti-TNF; Inﬂammatory Bowel Disease;
CDAI.
rohn’s disease (CD) often requires intestinal resec-Ction, despite treatment with immunosuppressive
and biologic therapies.1,2 Historically, up to 70% of patients
who undergo CD-related resection develop postoperative
endoscopic recurrence at or proximal to the surgical anas-
tomosis within 1 year.3,4 Recent systematic reviews and
meta-analyses have shown that approximately one-third of
patients with CD who have a ﬁrst resection require a second
within 10 years, and the majority of these second intestinal
resections occur within 5 years of the ﬁrst. However, during
the past few decades, the risk of a second resection has
decreased.5 Additionally, a decreasing trend has been found
during the past 6 decades in the cumulative risk of resection
1, 5, and 10 years after CD diagnosis.6
Studies of probiotics, aminosalicylates, and
budesonide7–13 for prevention of postoperative recurrence
have overall yielded negative results. Studies of nitro-
imidazole antibiotics have been positive for prevention of
clinical recurrence. Studies of thiopurines have had mixed
results for the prevention of clinical recurrence. Neither
nitroimidazole antibiotics nor thiopurines have consistently
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ATprevented endoscopic recurrence.14–16 Initial studies,17,18 a
small placebo-controlled trial,19 and subsequent observa-
tional studies20–25 suggested that tumor necrosis factor
(TNF) antagonists might be effective for prevention of
postoperative recurrence. In recent studies of CD treatment
strategies after intestinal resection, therapy adjusted
according to 6-month colonoscopy ﬁndings led to effective
disease control.26–28 Overall, optimal postoperative man-
agement is unclear.
Given these considerations, we evaluated the efﬁcacy
and safety of inﬂiximab for prevention of postoperative CD
recurrence.CL
IN
IC
AMethods
Patients
The PREVENT (Prospective, Multicenter, Randomized,
Double-Blind, Placebo-Controlled Trial Comparing REMI-
CADE® [inﬂiximab] and Placebo in the Prevention of
Recurrence in Crohn’s Disease Patients Undergoing Surgical
Resection Who Are at an Increased Risk of Recurrence;
ClinicalTrials.gov ID NCT01190839) study was a phase 3,
multicenter, placebo-controlled, double-blind, randomized
study conducted at 104 sites globally between November
2010 and May 2012. The Institutional Review Board or ethics
committee at each site approved the protocol, and patients
provided written informed consent. All authors had access to
the study data and had reviewed and approved the ﬁnal
manuscript.
Enrolled patients were at least 18 years old with a
conﬁrmed diagnosis of CD who had undergone ileocolonic
resection with ileocolonic anastomosis. An end or loop
ileostomy within 1 year was permitted if stoma closure and
ileocolonic anastomosis occurred within 45 days of random-
ization. Patients had no evidence of macroscopic CD, no
known active CD elsewhere in the gastrointestinal tract, and
were eligible for randomization within 45 days of resection.
Patients were ineligible if the qualifying surgery occurred
more than 10 years after CD diagnosis and was performed for
stricturing disease involving <10 cm of bowel. Patients were
also required to have a baseline CD Activity Index (CDAI)29
score <200 and at least one of the following risk factors for
disease recurrence: qualifying surgery that was their second
intra-abdominal resection within 10 years; third or more
intra-abdominal resection; resection for a penetrating CD
complication (eg, abscess or ﬁstula); a history of perianal
ﬁstulizing CD, provided the event had not occurred within 3
months; or smoking 10 or more cigarettes per day for the past
year. The prespeciﬁed risk factors of smoking, perforating
disease, and previous resection had been identiﬁed from
previous studies and were utilized in a recent postoperative
study.28,30–35
Patients receiving oral mesalamine or immunosuppressives
(azathioprine, 6-mercaptopurine, or methotrexate) pre-surgery
could continue treatment with maintenance of stable doses
after resection. Patients not receiving these agents pre-surgery
could not receive them post-surgery. Rectal mesalamine was
discontinued at least 2 weeks before randomization. Initiation
of corticosteroids or antibiotics for CD treatment was
prohibited.Study Design
Patients were randomized equally to receive inﬂiximab
(Remicade; Janssen Biotech, Inc., Horsham Township, PA) 5
mg/kg or placebo every 8 weeks. Placebo and inﬂiximab in-
fusions were administered in a blinded manner. Randomiza-
tion was stratiﬁed by the number of risk factors for
recurrence (1 or >1) and current use of an immunosup-
pressive (yes/no). Unlike dosing regimens used previously
and those described in the prescribing information for pa-
tients with CD,36 every-8-weeks dosing without the 3-dose
induction regimen was utilized in this study. This dosing
regimen was chosen because patients in this study were in
surgically-induced remission and did not have active CD at
the time they entered the study; thus, every-8-weeks dosing
for maintenance of remission was employed. Also, some pa-
tients might not have been naïve to inﬂiximab, and data from
an inﬂiximab trial in patients with psoriasis showed a higher
rate of serious infusion reactions at the week-2 inﬂiximab
infusion after a hiatus.37
CDAI scores were determined at each visit, and as
required at interim assessments; baseline CDAI refers to the
CDAI collected during the screening period (ie, no fewer than
10 days and no more than 45 days before randomization)
that qualiﬁed the patient for the study. Patients who met
CDAI criteria (ie, 200 and an increase of 70 points from
the baseline CDAI score) for clinical recurrence or reached
week 76 underwent a video ileocolonoscopy. Patients who
discontinued study agent before week 76 had a video ileo-
colonoscopy at the time of discontinuation. If clinical recur-
rence was observed, patients could receive blinded
inﬂiximab doses at an increase of 5 mg/kg for each subse-
quent scheduled infusion visit, such that patients receiving
placebo increased to 5 mg/kg and patients receiving 5 mg/kg
to 10 mg/kg.
Serum samples were collected at baseline and week 72 for
measurement of inﬂiximab and antibodies to inﬂiximab (ATI).38
Adverse events, concomitant medications, and CD-related hos-
pitalizations and surgeries were recorded throughout.
End Points
The primary end point was clinical recurrence before or at
week 76, deﬁned by a 70-point increase from baseline with a
total CDAI score 200 and evidence of endoscopic recurrence
deﬁned by a Rutgeerts score3 of i2 (i0, no lesions; i1, 5
aphthous lesions; i2, >5 aphthous lesions or anastomotic ulcer
<1 cm; i3, diffuse aphthous ileitis with diffusely inﬂamed mu-
cosa; i4, diffuse inﬂammation with large ulcers, nodules, and/or
narrowing) at the anastomotic site or its equivalent elsewhere
in the gastrointestinal tract or ﬁstula/abscess development (ie,
new draining external ﬁstula, internal ﬁstula, reopening and
draining of a previously existing external ﬁstula, perianal ab-
scess, or intra-abdominal abscess >3 months after the index
surgery). Patients were considered to have clinical recurrence if
they had a treatment failure (ie, initiated a prohibited CD
medication, had a prohibited use of a CD medication, or had CD-
related surgery).
The major secondary end point was endoscopic recurrence
of CD before or at week 76, deﬁned as a Rutgeerts score of i2
either at the anastomosis or elsewhere in the gastrointestinal
tract, whether this occurred at the week 76 video ileocolono-
scopy, or at a prior video ileocolonoscopy. Patients who
Table 1.Baseline Demographics, Disease Characteristics, and Concomitant Crohn’s Disease Medications for
Randomized Patients
Characteristic Placebo (N ¼ 150) Inﬂiximab 5 mg/kg (N ¼ 147) Total (N ¼ 297)
Sex, n (%)
n 150 147 297
Male 81 (54.0) 77 (52.4) 158 (53.2)
Female 69 (46.0) 70 (47.6) 139 (46.8)
Race, n (%)
n 150 147 297
White 138 (92.0) 138 (93.9) 276 (92.9)
Black or African American 4 (2.7) 3 (2.0) 7 (2.4)
Asian 2 (1.3) 1 (0.7) 3 (1.0)
Other 6 (4.0) 5 (3.4) 11 (3.7)
Age, y
n 150 147 297
Mean (SD) 35.4 (12.41) 37.1 (13.49) 36.3 (12.96)
Median 34.0 35.0 34.0
Interquartile range (25.044.0) (26.045.0) (26.044.0)
Range (1869) (1876) (18 76)
Weight, kg
n 150 147 297
Mean (SD) 69.70 (16.083) 69.64 (17.716) 69.67 (16.883)
Median 67.30 66.00 66.80
Interquartile range (58.1078.10) (57.2079.50) (58.0078.30)
Range (41.0127.0) (40.0125.7) (40.0127.0)
Disease duration, y
n 150 146 296
Mean (SD) 6.39 (7.457) 8.38 (8.651) 7.37 (8.115)
Median 3.32 6.49 5.17
Interquartile range (0.749.71) (1.4511.07) (0.8010.61)
Range (0.137.5) (0.145.9) (0.145.9)
CDAI score
n 150 146 296
Mean (SD) 109.8 (54.75) 107.7 (52.75) 108.8 (53.69)
Median 109.5 102.5 105.5
Interquartile range (66.0153.0) (64.0148.0) (65.0152.5)
Range (4240) (3202) (3240)
Involved gastrointestinal areas, n (%)
n 150 146 296
Ileum 146 (97.3) 144 (98.6) 290 (98.0)
Colon 76 (50.7) 89 (61.0) 165 (55.7)
Proximal small intestine, stomach and/or esophagus 6 (4.0) 6 (4.1) 12 (4.1)
Perianal 13 (8.7) 17 (11.6) 30 (10.1)
Extra intestinal manifestations 15 (10.0) 21 (14.4) 36 (12.2)
Findings at surgery, n (%)
n 150 146 296
Stricture 86 (57.3) 84 (57.5) 170 (57.4)
Abscess 41 (27.3) 47 (32.2) 88 (29.7)
Internal ﬁstula 86 (57.3) 67 (45.9) 153 (51.7)
Sinus tracts 10 (6.7) 7 (4.8) 17 (5.7)
Perforation 12 (8.0) 19 (13.0) 31 (10.5)
Prior intra-abdominal surgeries, n (%)
n 150 146 296
0 91 (60.7) 79 (54.1) 170 (57.4)
12 51 (34.0) 63 (43.2) 114 (38.5)
>2 8 (5.3) 4 (2.7) 12 (4.1)
CD medication history, n (%)
n 150 146 296
Any CD medication 144 (96.0) 136 (93.2) 280 (94.6)
Anti-tumor necrosis factor 30 (20.0) 37 (25.3) 67 (22.6)
Adalimumab 17 (11.3) 21 (14.4) 38 (12.8)
Inﬂiximab 15 (10.0) 18 (12.3) 33 (11.1)
Certolizumab 0 3 (2.1) 3 (1.0)
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Table 1.Continued
Characteristic Placebo (N ¼ 150) Inﬂiximab 5 mg/kg (N ¼ 147) Total (N ¼ 297)
Corticosteroid (excluding budesonide) 96 (64.0) 104 (71.2) 200 (67.6)
Budesonide 67 (44.7) 63 (43.2) 130 (43.9)
Immunosuppressive drugs 88 (58.7) 85 (58.2) 173 (58.4)
6-MP 22 (14.7) 19 (13.0) 41 (13.9)
AZA 77 (51.3) 73 (50.0) 150 (50.7)
Methotrexate 7 (4.7) 11 (7.5) 18 (6.1)
Mesalamine 101 (67.3) 100 (68.5) 201 (67.9)
Antibiotics 88 (58.7) 94 (64.4) 182 (61.5)
Concomitant CD medications, n (%)
n 150 147 297
Any CD medication 47 (31.3) 53 (36.1) 100 (33.7)
Corticosteroid (excluding budesonide) 4 (2.7) 10 (6.8) 14 (4.7)
20 mg/d P.Eq 0 1 (0.7) 1 (0.3)
<20 mg/d P.Eq 4 (2.7) 9 (6.1) 13 (4.4)
Budesonide 2 (1.3) 2 (1.4) 4 (1.3)
Immunosuppressive drugs 27 (18.0) 25 (17.0) 52 (17.5)
6-MP/AZA 27 (18.0) 21 (14.3) 48 (16.2)
Methotrexate 0 4 (2.7) 4 (1.3)
Mesalamine 27 (18.0) 28 (19.0) 55 (18.5)
AZA, azathioprine; 6-MP, 6-mercaptopurine; P.Eq, prednisone equivalent.
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considered to have endoscopic recurrence.
Endoscopic recurrence before or at week 76 deﬁned by
endoscopic score only (Rutgeerts score i2) was also analyzed.
Endoscopy end points before or at week 76, including those for
the primary end point, were evaluated by a central reader
(P.R.).
A secondary efﬁcacy end point was clinical recurrence
before or at week 104.
Study Duration
Although treatment was planned for a maximum of 208
weeks, the study was terminated after week 104 because the
primary outcome was not met.
Statistical Analysis
All randomized patients were included in efﬁcacy analyses
according to assigned treatment, regardless of actual treatment
received. All patients who received at least 1 dose of study
agent were included in safety and pharmacokinetic analyses
based on actual treatment received.
For continuous outcomes, the last value before treatment
failure was carried forward.
Seven sensitivity analyses were performed (5 prespeciﬁed
and 2 post-hoc) on the primary end point.
Odds ratios for prespeciﬁed subgroup analyses (eg, de-
mographics, disease characteristics, concomitant medications)
of clinical recurrence were summarized.
Categorical data (eg, clinical or endoscopic recurrence)
were compared using the Cochran-Mantel-Haenszel c2 test.
Continuous measures were compared using analysis of vari-
ance on the van der Waerden normal scores. Time-to-event
end points were analyzed using the log-rank test. A Cox
model was used to evaluate predictors of clinical recurrence.Statistical testing was performed at a ¼ .05 (2-sided) level of
signiﬁcance.
A ﬁxed-sequence testing procedure controlled the overall
type I error rate at the .05 level. If the test for the primary end
point was not positive, statistical tests for other end points
were not considered positive, even if the nominal P value
reached the .05 level of signiﬁcance.
In a study conducted with a patient population similar to
that proposed for this study, approximately 40% of patients in
the placebo group experienced clinical recurrence by week
52.19 For calculation of sample size, 50% and 30% of placebo-
and inﬂiximab-treated patients, respectively, were expected to
develop clinical recurrence by week 76. A sample size of 290
patients, 145 per treatment, provided 93% power to detect a
20% between-group difference in clinical recurrence before or
at week 76.Results
Patients
Demographics, qualifying characteristics, and risk fac-
tors of the 297 randomized patients (placebo, N ¼ 150;
inﬂiximab, N ¼ 147) were similar between treatment
groups. The most common risk factor for intestinal resection
was penetrating complication (Table 1, Supplementary
Tables 2 and 3). Approximately 20% of randomized pa-
tients received concomitant immunosuppressives (Table 1).
Antibiotics were administered for CD to 6 patients in the
placebo group and 2 patients in the inﬂiximab 5 mg/kg
group; these patients were considered treatment failures.
Patient disposition is shown in Supplementary Figure 1.
Approximately one-third of randomized patients dis-
continued study drug before week 76, most commonly for
adverse events.
Figure 1. Clinical recurrence before or at week 76 and before
or at week 104. P values based on the Cochran-Mantel-
Haenszel c2 test stratiﬁed by the number of risk factors for
recurrence of active Crohn’s disease (1 or >1) and baseline
use (yes/no) of an immunosuppressives (ie, azathioprine,
6-mercaptopurine, or methotrexate). aNominal P value.
Table 2.Reasons for Clinical Recurrencea Before or at
Week 76
Reasons
Placebo
(N ¼ 150)
Inﬂiximab,
5 mg/kg
(N¼147)
Met CDAI and endoscopic criteria 14 (9.3) 6 (4.1)
Met ﬁstula/abscess criteria 7 (4.7) 3 (2.0)
Developed a new draining external
ﬁstula
2 (1.3) 0
Reopened and drained a previously
existing external ﬁstula
0 1 (0.7)
Developed a new internal ﬁstula 3 (2.0) 2 (1.4)
Developed a new perianal abscess 6 (4.0) 1 (0.7)
Developed a new intra-abdominal
abscess >3 mo after the date of
the index surgery
0 1 (0.7)
Had a treatment failure 14 (9.3) 14 (9.5)
Initiated a prohibited CD medication 7 (4.7) 4 (2.7)
Had a prohibited use of a CD
medication
12 (8.0) 12 (8.2)
Had a surgery for CD 2 (1.3) 2 (1.4)
Met at least 1 of the following criteria 1 (0.7) 0
Discontinued study agent due to
recurrent symptoms of CD
0 0
Met CDAI criteria at the time of
discontinuation of study agent
1 (0.7) 0
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Clinical recurrence rates before or at week 76 were
12.9% and 20.0% for the inﬂiximab and placebo groups,
respectively (absolute risk reduction [ARR] with inﬂiximab,
7.1%; 95% conﬁdence interval [CI]: 1.3% to 15.5%); these
results were not statistically signiﬁcant (P ¼ .097)
(Figure 1). Of note, clinical recurrence rates before or at
week 76 among patients who met both CDAI and endo-
scopic criteria were 4.1% and 9.3% (P ¼ .056) for the
inﬂiximab and placebo groups, respectively (Table 2).
In general, the results of the sensitivity analyses were
consistent with the results of the primary end point analysis
(Supplementary Table 1).
Time to clinical recurrence is summarized in Figure 2 for
the inﬂiximab and placebo groups (log rank P ¼ .141).
Results observed in prespeciﬁed subgroups were
generally consistent with the overall results, with a few
exceptions, including CD duration, baseline CDAI score,
prior TNF therapy, race, geographic location, disease loca-
tion in gastrointestinal tract, and patients undergoing their
second intra-abdominal operation (Supplementary
Figure S2AD).Did not have sufﬁcient data to evaluate
clinical recurrence status at both wk
72 and wk 76
0 0
NOTE. Values are n (%).
aPatients could have more than one reason for clinical
recurrence.Secondary End Points
Endoscopic recurrence. Endoscopic recurrence, as
deﬁned by Rutgeerts score i2; or abscess, ﬁstula recur-
rence, or development; or treatment failure, before or at
week 76 for the inﬂiximab and placebo groups was 30.6%and 60.0%, respectively (ARR with inﬂiximab ¼ 29.4%;
95% CI: 18.6%40.2%; P < .001; Figure 3A).
Similarly, endoscopic recurrence deﬁned only by Rut-
geerts scores i2 for the inﬂiximab and placebo groups was
22.4% and 51.3%, respectively (ARR with inﬂiximab ¼
28.9%; 95% CI: 18.4% 39.4%; P < .001; Figure 3A).
Classiﬁcation of patients by Rutgeerts score i1 (<5
aphthous ulcers) and i2 (5 aphthous ulcers or anastomotic
ulcer <1 cm) endoscopic recurrence may be of negligible
clinical signiﬁcance and potentially separated by only 1
aphthous ulcer. Classifying patients by normal mucosa (i0)
or aggressive endoscopic recurrence (i3/i4) provides a
more meaningful distinction.
Central endoscopic results before or at week 76 are
presented in Figure 3B. Of 73 patients with an i0 Rutgeerts
score before or at week 76, 54 (74.0%) and 19 (26.0%)
patients were in inﬂiximab and placebo groups, respectively
(Supplementary Figure S3). Of 59 patients with an i3 or i4
Rutgeerts score before or at week 76, 11 (18.6%) and 48
(81.4%) patients were in the inﬂiximab and placebo groups,
respectively (Supplementary Figure S3).
Among patients with endoscopy results before or at
week 76, the distribution of Rutgeerts scores are summa-
rized in Figure 3B.
Clinical recurrence at week 104. Clinical recurrence
rates before or at week 104 were 17.7% and 25.3% for the
Figure 2. Time to ﬁrst clinical recurrence before or at week
76; all randomized patients.
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inﬂiximab ¼ 7.6%, 95% CI: 1.7%, to 17.0%; P ¼ .098)
(Figure 1).
Crohn’s Disease Activity Index scores at week
104. Median changes from baseline in CDAI score at the
last visit before or at week 104 were 15.0 and 22.0 for
placebo and inﬂiximab 5 mg/kg, respectively (P ¼ .058).
Median CDAI scores through week 104 are shown in
Supplementary Figure S4.Hospitalizations and Surgeries
Hospitalizations and surgeries were uncommon, with no
statistically signiﬁcant differences observed between groups
through week 104 (Supplementary Table 4).
Predictors of Clinical Recurrence
Patients with more than one resection or who received
anti-TNF therapy pre-surgery were more likely to have a
clinical recurrence (Supplementary Table 5).
Safety
Among 297 randomized patients, 291 received at least
1 dose of study drug. The average duration of treatment
before a dose increase was similar for inﬂiximab and
placebo (74.3 weeks and 75.9 weeks, respectively;
Table 3).
Adverse and serious adverse event rates were similar
between groups. Infection rates, including serious in-
fections, were also similar. More patients in the inﬂiximab
than placebo group discontinued therapy because of an
adverse event through the ﬁnal visit, most commonly for
adverse events related to the gastrointestinal or infection
and infestation system organ class (Supplementary Table 6).There were no deaths or malignancies (excluding non-
melanoma skin cancer) in inﬂiximab-treated patients
(Table 3).
Infusion reactions occurred in 8.2% of placebo-treated
compared with 19.4% of inﬂiximab-treated patients
(Table 3).
Pharmacokinetics and Immunogenicity
For patients in the inﬂiximab 5 mg/kg group, me-
dian trough serum inﬂiximab concentrations were 0.00
mg/mL and 2.18 mg/mL at week 0 and week 72,
respectively.
At week 72, median serum inﬂiximab concentration for
patients receiving immunosuppressives was numerically
greater than those not receiving immunosuppressives (4.89
mg/mL vs 1.83 mg/mL, respectively). The proportion of
inﬂiximab-treated patients with endoscopic recurrence
before or at week 76 decreased with increasing serum
inﬂiximab concentration. This effect was not observed for
clinical recurrence (Supplementary Figure S5).
Overall, ATIs were present in 16.2% of patients, none of
whom were receiving immunosuppressives at baseline. This
ATI incidence was based on an antigen-bridging enzyme
immunoassay in which detectable levels of circulating
inﬂiximab can interfere with the ability to assess the pres-
ence of ATI. Endoscopic recurrence before or at week 76
was seen in 64.7% (11 of 17), 46.7% (7 of 15), and 30.1%
(22 of 73) of patients who were positive, negative, or
inconclusive for ATI, respectively. This effect was not
observed for clinical recurrence.
Discussion
This study evaluating inﬂiximab for prevention of
post-surgical CD recurrence after ileocolonic resection
did not meet the primary end point of clinical recurrence
and was prematurely terminated at week 104. The
endoscopic recurrence rate in inﬂiximab-treated patients
is consistent with those of small randomized controlled
trials.18,19
We also found that patients with a prior resection and
use of anti-TNF therapy pre-surgery were at higher risk for
postoperative CD recurrence. However, it is possible that
these factors reﬂect disease severity and/or complicated
disease course rather than independent risk factors for
recurrence. These results should be interpreted with
caution due to the small sample size.
The PREVENT trial is the ﬁrst large, multicenter,
placebo-controlled postoperative CD study with a bio-
logic. Assumptions on postoperative clinical and endo-
scopic recurrence were extrapolated from the collective
results of several smaller studies, including the trial by
Regueiro et al.19 Patients enrolled in that small study may
have had a higher risk of postoperative CD recurrence,
most with penetrating disease and a high proportion
having undergone at least 2 resections. The intent of the
PREVENT study was to enroll a similar high-risk popula-
tion of patients; however, 69.6% had only one risk factor
for recurrence, and 57.4% were undergoing their ﬁrst
Figure 3. Endoscopic recurrence before or at week 76; all
randomized patients (A) and central endoscopic results
before or at week 76 (Rutgeerts score i0, i1, i2, i3, i4) (B). P
values based on the Cochran-Mantel-Haenszel c2 test
stratiﬁed by the number of risk factors for recurrence of active
Crohn’s disease (1 or >1) and baseline use (yes/no) of an
immunosuppressives (ie, azathioprine, 6-mercaptopurine, or
methotrexate). aNominal P value. i0, no lesions; i1, 5 aph-
thous lesions; i2, >5 aphthous lesions or anastomotic ulcer
<1 cm; i3, diffuse aphthous ileitis with diffusely inﬂamed
mucosa; i4, diffuse inﬂammation with large ulcers, nodules,
and/or narrowing.
1574 Regueiro et al Gastroenterology Vol. 150, No. 7
CLINICAL
ATintestinal resection. This may account for the difference in
the placebo clinical recurrence rate before or at week 76
in PREVENT (20.0%) and the 12-month rate reported
previously (38.5%).19
It should be noted that although the risk factors for
postoperative recurrence, that is, cigarette smoking,recurrent surgery, and penetrating disease, have been
included in numerous previous studies,4,26,30–35 these fac-
tors have never been formally validated or replicated.
Likewise, the combination of factors would presume a
higher risk of postoperative recurrence; this additive effect
has also not been replicated. Therefore, the stratiﬁcation of
risk based on the small sample size of the Regueiro trial may
have resulted in an overestimation of effect in PREVENT.
The low baseline median CDAI score of 105.5 required
many patients to double their CDAI score during the course
of the study to meet the clinical recurrence criterion of CDAI
200. This possibly contributed to the small proportions of
patients (inﬂiximab, 4.1%; placebo, 9.3%) who met both
CDAI and endoscopic criteria for clinical recurrence before
or at week 76. Furthermore, only 17.5% of patients received
concomitant immunosuppressives compared with 45.8% of
patients in the Regueiro trial.19 Administration of immu-
nosuppressives increases inﬂiximab levels, reduces immu-
nogenicity, and increases efﬁcacy of inﬂiximab.39
Patients in PREVENT underwent a video ileocolonoscopy
at week 76, when CDAI criteria met the deﬁnition of clinical
recurrence, or when they discontinued the study. Week 76,
rather than week 24 or 48, was selected as the primary time
point due to the combined clinical and endoscopic end
point. Clinical recurrence within the ﬁrst year after resec-
tion is low, as endoscopic recurrence often occurs initially
without clinical symptoms.3,40–43
We hypothesized that waiting 18 months after
resection for primary composite end point assessment
would be sufﬁcient to detect clinical recurrence without
endoscopic recurrence causing severe, irreversible
bowel damage. Additionally, when the PREVENT study
was designed (2009), only one small proof-of-concept
study19 and an open-label experience18 in postoperative
patients with CD treated with anti-TNF therapies were
published to guide the timing and deﬁnition of clinical
end points.
Our selection of a composite end point appeared to be
supported by a subsequent publication by Walters et al,44
who explored the utility of the CDAI in determining symp-
tomatic disease recurrence in patients having previously
undergone ileocolonic resection for CD, and concluded that
“a combination of symptom assessment plus endoscopic
evidence of recurrence should remain the gold standard
deﬁnition for assessing outcomes in postoperative CD tri-
als.” However, it must be acknowledged that the composite
end point prospectively implemented here was not formally
validated in this clinical setting.
Because early endoscopic recurrence appears to corre-
late with future clinical recurrence and the need for resec-
tion,3 it is currently recommended that patients with CD
undergo a surveillance ileocolonoscopy 6 to 12 months
postoperatively to assess for endoscopic recurrence.40–43
Recent studies have suggested that TNF-antagonists are
effective in this setting based on therapy adjusted
according to 6-month postoperative colonoscopy
ﬁndings.26–28
There are limitations to the study. Inﬂiximab might have
been started as late as 45 days after resection, by which
Table 3.Key Safety Findings Through Week 104 for Treated Patients
Variable
Placeboa
(N ¼ 146)
Inﬂiximab,
5 mg/kga,b
(N ¼ 145)
Inﬂiximab (dose increase)
All inﬂiximabd
(N ¼ 170)
Placebo/inﬂiximab,
5 mg/kgc (n ¼ 25)
Inﬂiximab
5 mg/kg/inﬂiximab,
10 mg/kgc (n ¼ 9)
Mean duration of follow-up, wk 85.4 85.7 50.6 39.4 82.6
Mean duration of treatment, wk 75.9 74.3 32.4 13.9 68.9
Patients with 1 adverse events, n (%) 132 (90.4) 133 (91.7) 19 (76.0) 7 (77.8) 152 (89.4)
Patients with 1 serious adverse
events, n (%)
32 (21.9) 28 (19.3) 3 (12.0) 2 (22.2) 32 (18.8)
Patients who discontinued study agent
because of 1 adverse events, n (%)
13 (8.9) 35 (24.1) 10 (40.0) 5 (55.6) 50 (29.4)
Patients who died, n (%) 1 (0.7) 0 0 0 0
Patients with 1 or more
malignancies,e n (%)
2 (1.4) 0 0 0 0
Patients with 1 infections, n (%) 85 (58.2) 84 (57.9) 8 (32.0) 4 (44.4) 93 (54.7)
Patients with 1 serious infections, n (%) 9 (6.2) 7 (4.8) 1 (4.0) 1 (11.1) 9 (5.3)
Patients with 1 infusion reaction,f n (%) 12 (8.2) 26 (17.9) 7 (28.0) 1 (11.1) 33 (19.4)
aIncludes data up to the time of dose increase for those who increased dose. Six patients were randomized but not treated and
analyzed for efﬁcacy only, and 2 patients inadvertently received inﬂiximab 5 mg/kg and analyzed for safety as inﬂiximab-
treated patients.
bTwo patients were randomized to the placebo group, but received one infusion of inﬂiximab. These patients were analyzed in
the inﬂiximab 5 mg/kg group for safety.
cIncludes data from the time of dose increase onward.
dIncludes data from the time of the ﬁrst inﬂiximab dose onward.
eMalignancies excluding nonmelanoma skin cancers were deﬁned by individual event terms in neoplasms benign, malignant,
and unspeciﬁed (including cysts and polyps) system organ class.
fAn infusion reaction was deﬁned as any adverse event that occurred during or within 1 hour of the administration of the study
agent infusion.
June 2016 Inﬂiximab for Postsurgical CD Prevention 1575
CL
IN
IC
AL
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This would mean that treatment was initiated in response to
active inﬂammation rather than prevention of CD recur-
rence. The rationale for waiting 45 days was to ensure at
least 14 to 21 days passed with no surgical resection
complication, and to allow enough time for the CDAI
collection and additional patient screening. The median time
between resection and ﬁrst study infusion was 36.5 days for
placebo and 35 days for inﬂiximab 5 mg/kg, and is unlikely
to have altered the results signiﬁcantly. While we designed
the study to use every-8-weeks maintenance infusions after
resection, it is possible that the 3-dose induction and
concomitant use of immunosuppressants could have led to
even lower recurrence rates, as described previously,40 and
reduced immunogenicity.
While prevention of clinical recurrence was not ach-
ieved, inﬂiximab-treated patients achieved a lower endo-
scopic recurrence rate than those assigned to placebo.
Consistent with other studies using anti-TNF thera-
pies,17,18,25,45 inﬂiximab-treated patients had lower recur-
rence deﬁned by endoscopic criteria only.
The primary end point of clinical recurrence may be
inﬂuenced by symptom-based CDAI score, which consists of
diarrhea, abdominal pain, and general well-being compo-
nents that might be neither sensitive nor speciﬁc for
mucosal inﬂammation, which is integral to disease recur-
rence.46 Regueiro and colleagues47 also found no correlationbetween CDAI scores and endoscopic disease activity 1 year
after ileocolonic resection, with the majority of patients in
clinical remission (CDAI <150) despite endoscopic
recurrence.
The severity of endoscopic recurrence has a high pre-
dictive value for the need for future resection.3,48 If the
goal of mucosal healing and maintenance of intestinal
normalcy, rather than symptom control alone, are relevant
inﬂammatory bowel disease management targets, then a
postoperative strategy for prevention of endoscopic
recurrence may be clinically relevant, especially for high-
risk patients.49,50 Given the high rates of clinically silent,
but endoscopically active, CD within 2 years of resection,
we suggest that future postoperative studies utilize
objective rather than subjective criteria for active CD, and
have the primary assessment no more than 1 year after
resection.
A postoperative strategy of escalating treatment for
endoscopic recurrence at 6 months was evaluated in the
POCER (Post-Operative Crohn’s Disease Endoscopic
Recurrence) study.28 Patients were risk-stratiﬁed (high vs
low) for CD recurrence then randomized to have an initial
colonoscopy at 6 months or no colonoscopy until 18
months. All patients received 3 months of metronidazole, if
tolerated, and high-risk patients were treated with post-
operative thiopurine, or if previously intolerant, adalimu-
mab. Patients undergoing a 6-month colonoscopy were
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recurrence. The primary end point of the POCER study was
postoperative endoscopic recurrence at 18 months. The
18-month endoscopic recurrence rate in patients previ-
ously undergoing a colonoscopy at 6 months was 49%
compared with 67% in those who had not had a 6-month
colonoscopy. The 6-month endoscopic recurrence rate in
high-risk patients receiving thiopurine was 45% compared
with 21% with anti-TNF therapy and is similar to the 18-
month endoscopic recurrence rate in the PREVENT trial
(51.3% in placebo and 22.4% in inﬂiximab). Therefore, it
may be reasonable to approach low-risk patients under-
going their ﬁrst resection for CD conservatively and initiate
treatment only if there is endoscopic recurrence at 6
months. High-risk patients with recurrent intestinal
resection for CD should be considered for postoperative
anti-TNF therapy.
In conclusion, inﬂiximab was not signiﬁcantly superior
for prevention of clinical recurrence after CD ileocolonic
resection, but did reduce endoscopic recurrence.
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